Heron shares fly up af­ter FDA (fi­nal­ly) ap­proves its drug to rein in chemo side ef­fects

Shares of Red­wood City, CA-based Heron Ther­a­peu­tics $HRTX shot up 20% on Wednes­day morn­ing af­ter the biotech an­nounced that the FDA has at long last ap­proved its sus­tained-re­lease for­mu­la­tion of Sus­tol (granisetron) to pre­vent nau­sea and vom­it­ing for pa­tients on chemo. The ap­proval comes af­ter a 6-year reg­u­la­to­ry odyssey for Heron, which start­ed with the first of two FDA re­jec­tions in 2010.

The in­jectable 5-HT3 re­cep­tor an­tag­o­nist us­es Heron’s poly­mer-based de­liv­ery tech to main­tain ef­fi­ca­cy for five or more days for pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.